All data are based on the daily closing price as of July 18, 2025
h
Hisamitsu Pharmaceutical
4530.TSE
27.16 USD
0.12
+0.44%
Overview
Last close
27.16 usd
Market cap
1.98B usd
52 week high
32.23 usd
52 week low
22.74 usd
Target price
32.59 usd
Valuation
P/E
15.1513
Forward P/E
N/A
Price/Sales
1.8895
Price/Book Value
1.0892
Enterprise Value
1.20B usd
EV/Revenue
1.1559
EV/EBITDA
6.9964
Key financials
Revenue TTM
1.05B usd
Gross Profit TTM
612.75M usd
EBITDA TTM
169.53M usd
Earnings per Share
1.79 usd
Dividend
0.58 usd
Total assets
2.28B usd
Net debt
-735.00M usd
About
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.